In line Q1 and on track deleveraging; worth a go
15/05/24 -"The Q1 results largely met the consensus, as the firm’s key blood-plasma-derived proteins witnessed strong demand, profitability continued to expand yoy and the deleveraging initiatives remained on ..."
Pages
56
Language
English
Published on
15/05/24
You may also be interested by these reports :
24/10/25
The Q3 operating profitability came in considerably ahead of the street’s estimates, though sales met expectations. The performance was driven by ...
23/10/25
The Q3 sales missed expectations by a small margin; however, the management upgraded its 2025 earnings outlook. The Pharmaceuticals segment was again ...
23/10/25
Lonza’s strong Q3 commentary reaffirmed its commitment to meeting the 2025 guidance, boosting investor sentiment. While operational figures were not ...
22/10/25
Ipsen’s Q3 sales surpassed expectations, showing robust growth across all segments. Consequently, the 2025 guidance has been revised upwards. The ...